Literature DB >> 32281583

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).

Jianjun Gao1, Shasha Hu2.   

Abstract

Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; chloroquine; hydroxychloroquine

Mesh：

Substances：

Year:  2020        PMID： 32281583     DOI： 10.5582/bst.2020.03072

Source DB:  PubMed          Journal:  Biosci Trends        ISSN： 1881-7815            Impact factor:   2.400


  13 in total

1.  Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine.

Authors:  Shehnoor Azhar; Javed Akram; Muhammad Shahzad; Waqas Latif; Khalid Saeed Khan
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

Review 2.  Known drugs and small molecules in the battle for COVID-19 treatment.

Authors:  Alexios A Panoutsopoulos
Journal:  Genes Dis       Date:  2020-06-20

Review 3.  Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?

Authors:  Daniele Giammaria; Alessandro Pajewski
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

Review 4.  Conjunctivitis as a Sentinel of SARS-CoV-2 Infection: a Need of Revision for Mild Symptoms.

Authors:  Alexios A Panoutsopoulos
Journal:  SN Compr Clin Med       Date:  2020-06-19

5.  Repurposing old drugs as antiviral agents for coronaviruses.

Authors:  Cheng-Wei Yang; Tzu-Ting Peng; Hsing-Yu Hsu; Yue-Zhi Lee; Szu-Huei Wu; Wen-Hsing Lin; Yi-Yu Ke; Tsu-An Hsu; Teng-Kuang Yeh; Wen-Zheng Huang; Jiunn-Horng Lin; Huey-Kang Sytwu; Chiung-Tong Chen; Shiow-Ju Lee
Journal:  Biomed J       Date:  2020-05-23       Impact factor: 4.910

Review 6.  Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection.

Authors:  Prasenjit Mitra
Journal:  Am J Physiol Cell Physiol       Date:  2020-07-20       Impact factor: 4.249

Review 7.  Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.

Authors:  Priyasha De; Ishita Chakraborty; Bhargavi Karna; Nirmal Mazumder
Journal:  Eur J Pharmacol       Date:  2021-02-25       Impact factor: 4.432

8.  The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.

Authors:  Naser Gharebaghi; Rahim Nejadrahim; Seyed Jalil Mousavi; Seyyed-Reza Sadat-Ebrahimi; Reza Hajizadeh
Journal:  BMC Infect Dis       Date:  2020-10-21       Impact factor: 3.090

Review 9.  COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.

Authors:  Hussain Ahmed Raza; Javeria Tariq; Vikas Agarwal; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-01-01       Impact factor: 2.631

10.  Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.

Authors:  Frank H Annie; Cristian Sirbu; Keely R Frazier; Mike Broce; B Daniel Lucas
Journal:  Pharmacotherapy       Date:  2020-11       Impact factor: 6.251
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.